No Data
No Data
Zhejiang Medicine Co., Ltd.'s (SHSE:600216) Stock Is Going Strong: Have Financials A Role To Play?
Zhejiang Medicine (SHSE:600216) has had a great run on the share market with its stock up by a significant 26% over the last three months. Given that stock prices are usually aligned with a company'
Zhejiang Medicine (600216.SH) will distribute equity for the year 2023: 0.15 yuan per share.
Zhejiang Medicine (600216.SH) announced the implementation of equity distribution for the year 2023: before the implementation of the plan...
Individual Investors in Zhejiang Medicine Co., Ltd. (SHSE:600216) Are Its Biggest Bettors, and Their Bets Paid off as Stock Gained 5.9% Last Week
Key Insights Significant control over Zhejiang Medicine by individual investors implies that the general public has more power to influence management and governance-related decisions The top 25 sha
China Grants Clinical Trial Approval for Zhejiang Medicine's Antibacterial Injection
China's medical products administrator granted clinical trial approval to Zhejiang Medicine's (SHA:600216) LYSC98 injectable antibacterial drug indicated for common clinical gram-positive bacteria, ac
Zhejiang Medicine (SHSE:600216) Takes On Some Risk With Its Use Of Debt
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company is, we always like to look at its use of debt, since debt overload can lead to rui
Zhejiang Pharmaceutical (600216.SH): No plans to develop or sell weight loss drugs
Gelonghui, May 10 丨 Zhejiang Pharmaceutical (600216.SH) said on the investor interactive platform that the company currently has no plans to develop or sell weight loss drugs.
No Data